A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

Launched by CENTREXION THERAPEUTICS · Jun 22, 2018

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Body mass index (BMI) between 18.0-35.0 kg/m\^2
• • Subject has moderate to severe painful osteoarthritis in one knee while walking (index knee); contralateral knee may or may not have osteoarthritis, pain should be none to mild in the non-index knee
• • Confirmation of the OA of the index knee: American College of Rheumatology (ACR) diagnostic criteria
• • Subject has intact skin at the location of the dosing sites (patch or injection)
• Key Exclusion Criteria:
• • Subject has any other form of arthritis, such as, but not limited to, rheumatoid arthritis, psoriatic arthritis, gout, systemic lupus erythematosus, etc.
• • Subject has a dermatological condition that may contraindicate participation, including any compromise in skin integrity at the CNTX-4975-05 injection site or the Qutenza® skin application site, e.g., severe or cystic acne, psoriasis, eczema, atopic dermatitis, active or treated cancer, etc.